Liang Chen

PRODH promotes osimertinib drug-tolerant persistence in EGFR-mutant NSCLC by activating mitochondrial transcription.

The emergence of drug-tolerant persister (DTP) cells poses a major obstacle to durable responses to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC). However, how metabolic programming orchestrates this transient and reversible adaptive resistance remains largely unexplored. Here...